In 48 patients with persistent Crohn's perianal fistula, autologous cell therapy AVB-114 gave higher combined remission at 36 weeks than standard of care (45.8% vs 8.3%; P = 0.0078). Adverse events: 56 vs 40, none serious with AVB-114.
RCTn = 48
Schwartz et al. AVB-114 Demonstrates Clinical Benefit in Persistent Crohn's Perianal Fistulas: Randomized Cohort Results From the Multicenter STOMP2 Trial